Anna Sipos

Most-cited papers

1. Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors.

   G. Németh, Z. Greff, Anna Sipos, Z. Varga +15 more

   2014Journal of Medicinal Chemistry67 citations Open access

   Semantic Scholar

   Save

2. Lead selection and characterization of antitubercular compounds using the Nested Chemical Library.

   Anna Sipos, J. Pató, R. Székely, R. Hartkoorn +13 more

   2015Tuberculosis32 citations Open access

   Semantic Scholar

   Save

3. Novel, selective CDK9 inhibitors for the treatment of HIV infection.

   G. Németh, Z. Varga, Zoltán Greff, G. Bencze +9 more

   2011Current Medicinal Chemistry29 citations

   Semantic Scholar

   Save

4. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.

   R. Garamvölgyi, J. Dobos, Anna Sipos, S. Boros +7 more

   2016European journal of medicinal chemistry28 citations Open access

   Semantic Scholar

   Save

5. Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma.

   Zsófia Czudor, M. Balogh, P. Bánhegyi, S. Boros +10 more

   2018Bioorganic & Medicinal Chemistry Letters21 citations Open access

   Semantic Scholar

   Save

6. Targeted drug combination therapy design based on driver genes

   L. Zsákai, Anna Sipos, J. Dobos, D. Erős +9 more

   2019OncoTarget17 citations Open access

   Semantic Scholar

   Save

7. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.

   F. Baska, Anna Sipos, Zoltán Őrfi, Z. Nemes +11 more

   2019European journal of medicinal chemistry12 citations Open access

   Semantic Scholar

   Save

8. Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.

   Ferenc Baska, István Szabadkai, Anna Sipos, Nóra Breza +9 more

   2014Current Medicinal Chemistry11 citations

   Semantic Scholar

   Save

9. Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.

   L. Kékesi, Anna Sipos, G. Németh, J. Pató +4 more

   2013Bioorganic & Medicinal Chemistry Letters9 citations Open access

   Semantic Scholar

   Save

10. [Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction].

    L. Kékesi, Anna Sipos, G. Németh, A. Dancsó +9 more

    2014Acta pharmaceutica Hungarica3 citations

    Semantic Scholar

    Save

11. Lasting Complete Clinical Response of a Recurring Cutaneous Squamous Cell Carcinoma With MEK Mutation and PIK3CA Amplification Achieved by Dual Trametinib and Metformin Therapy.

    É. Remenár, R. Dóczi, A. Dirner, Anna Sipos +12 more

    2022JCO Precision Oncology2 citations

    Semantic Scholar

    Save

12. Signal transduction therapy of cancer with kinase inhibitors

    G. Kéri, L. Őrfi, Z. Greff, J. Pató +4 more

    20130 citations

    Semantic Scholar

    Save

13. Characterization of p53 activator compounds which inhibit a survival factor kinase as well

    R. Belle, F. Baska, Zoltan Örfi, C. Szántai-Kis +6 more

    20120 citations

    Semantic Scholar

    Save